EP4268900A3 - Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax - Google Patents

Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax Download PDF

Info

Publication number: EP4268900A3
Authority: EP; European Patent Office
Prior art keywords: treatment; lymphoma; venetoclax; antibody; paradigm
Prior art date: 2017-05-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP23190328.7A

Other languages

German (de)

English (en)

Other versions

EP4268900A2 (fr

Inventor

Peter Kelemen

Michael Schwarz

Mark Winderlich

Steffen HEEGER

Dominika WEINELT

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Incyte Corp

Original Assignee

Morphosys GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-05-31

Filing date

2018-05-30

Publication date

2024-03-06

2018-05-30 Application filed by Morphosys GmbH filed Critical Morphosys GmbH

2023-11-01 Publication of EP4268900A2 publication Critical patent/EP4268900A2/fr

2024-03-06 Publication of EP4268900A3 publication Critical patent/EP4268900A3/fr

Status Pending legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

EP23190328.7A 2017-05-31 2018-05-30 Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax Pending EP4268900A3 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP17173712		2017-05-31
PCT/EP2018/064229 WO2018220040A1 (fr)	2017-05-31	2018-05-30	Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax
EP18728153.0A EP3630177B1 (fr)	2017-05-31	2018-05-30	Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
EP18728153.0A Division EP3630177B1 (fr)	2017-05-31	2018-05-30	Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax

Publications (2)

Publication Number	Publication Date
EP4268900A2 EP4268900A2 (fr)	2023-11-01
EP4268900A3 true EP4268900A3 (fr)	2024-03-06

Family

ID=59070416

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP18728153.0A Active EP3630177B1 (fr)	2017-05-31	2018-05-30	Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax
EP23190328.7A Pending EP4268900A3 (fr)	2017-05-31	2018-05-30	Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP18728153.0A Active EP3630177B1 (fr)	2017-05-31	2018-05-30	Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax

Country Status (27)

Country	Link
US (1)	US20250186460A1 (fr)
EP (2)	EP3630177B1 (fr)
JP (2)	JP7399713B2 (fr)
KR (2)	KR20240117655A (fr)
CN (1)	CN110678201A (fr)
AU (2)	AU2018276384B2 (fr)
BR (1)	BR112019025034A2 (fr)
CA (1)	CA3062400A1 (fr)
CY (1)	CY1126559T1 (fr)
DK (1)	DK3630177T5 (fr)
ES (1)	ES2961940T3 (fr)
FI (1)	FI3630177T3 (fr)
HR (1)	HRP20231229T1 (fr)
HU (1)	HUE063119T2 (fr)
IL (2)	IL297461B2 (fr)
LT (1)	LT3630177T (fr)
MA (1)	MA48751B1 (fr)
MD (1)	MD3630177T2 (fr)
MX (2)	MX2019014330A (fr)
PL (1)	PL3630177T3 (fr)
PT (1)	PT3630177T (fr)
RS (1)	RS64746B1 (fr)
SG (1)	SG11201909715VA (fr)
SI (1)	SI3630177T1 (fr)
SM (1)	SMT202300338T1 (fr)
WO (1)	WO2018220040A1 (fr)
ZA (1)	ZA201907369B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2767063C2 (ru)	2015-08-21	2022-03-16	МорфоСис АГ	Комбинации и их использование
US12358983B2 (en) *	2016-10-28	2025-07-15	Incyte Corporation	Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
KR20200030337A (ko)	2018-09-12	2020-03-20	주식회사 녹십자랩셀	종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2022115120A1 (fr) *	2020-11-30	2022-06-02	Incyte Corporation	Polythérapie comprenant un anticorps anti-cd19 et le parsaclisib
EP4251138A1 (fr) *	2020-11-30	2023-10-04	Incyte Corporation	Polythérapie faisant appel à un anticorps anti-cd19 et à du parsaclisib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013024095A1 (fr) *	2011-08-16	2013-02-21	Morphosys Ag	Polythérapie avec anticorps anti-cd19 et analogue de purine
WO2013024097A1 (fr) *	2011-08-16	2013-02-21	Morphosys Ag	Polythérapie avec anticorps anti-cd19 et moutarde à l'azote
WO2018078123A1 (fr) *	2016-10-28	2018-05-03	Morphosys Ag	Combinaison d'anticorps anti-cd19 avec un inhibiteur de bcl -2 et utilisations de celle-ci

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2534639C (fr)	2003-07-31	2013-07-30	Immunomedics, Inc.	Anticorps anti-cd19
US7902338B2 (en)	2003-07-31	2011-03-08	Immunomedics, Inc.	Anti-CD19 antibodies
CA2611814A1 (fr)	2005-06-20	2007-01-04	Medarex, Inc.	Anticorps cd19 et utilisations
ES2365046T3 (es)	2005-12-30	2011-09-21	Merck Patent Gmbh	Anticuerpos anti-cd19 con inmunogenicidad reducida.
PL2383297T3 (pl)	2006-08-14	2013-06-28	Xencor Inc	Zoptymalizowane przeciwciała ukierunkowane na CD19
RU2495882C2 (ru)	2006-09-08	2013-10-20	Медиммун, Ллк.	Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
DK2211904T3 (en)	2007-10-19	2016-10-24	Seattle Genetics Inc	Cd19-binding agents and uses thereof
CN102421800A (zh)	2009-02-23	2012-04-18	格兰马克药品股份有限公司	结合cd19的人源化抗体及其用途
US8546399B2 (en)	2009-05-26	2013-10-01	Abbvie Inc.	Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2767063C2 (ru)	2015-08-21	2022-03-16	МорфоСис АГ	Комбинации и их использование

2018
- 2018-05-30 LT LTEPPCT/EP2018/064229T patent/LT3630177T/lt unknown
- 2018-05-30 EP EP18728153.0A patent/EP3630177B1/fr active Active
- 2018-05-30 SM SM20230338T patent/SMT202300338T1/it unknown
- 2018-05-30 MX MX2019014330A patent/MX2019014330A/es unknown
- 2018-05-30 KR KR1020247024908A patent/KR20240117655A/ko not_active Ceased
- 2018-05-30 PL PL18728153.0T patent/PL3630177T3/pl unknown
- 2018-05-30 AU AU2018276384A patent/AU2018276384B2/en active Active
- 2018-05-30 JP JP2019565795A patent/JP7399713B2/ja active Active
- 2018-05-30 SG SG11201909715V patent/SG11201909715VA/en unknown
- 2018-05-30 HU HUE18728153A patent/HUE063119T2/hu unknown
- 2018-05-30 HR HRP20231229TT patent/HRP20231229T1/hr unknown
- 2018-05-30 ES ES18728153T patent/ES2961940T3/es active Active
- 2018-05-30 IL IL297461A patent/IL297461B2/en unknown
- 2018-05-30 FI FIEP18728153.0T patent/FI3630177T3/fi active
- 2018-05-30 MD MDE20200316T patent/MD3630177T2/ro unknown
- 2018-05-30 MA MA48751A patent/MA48751B1/fr unknown
- 2018-05-30 KR KR1020197037961A patent/KR20200010472A/ko not_active Ceased
- 2018-05-30 CA CA3062400A patent/CA3062400A1/fr active Pending
- 2018-05-30 SI SI201831004T patent/SI3630177T1/sl unknown
- 2018-05-30 PT PT187281530T patent/PT3630177T/pt unknown
- 2018-05-30 BR BR112019025034-4A patent/BR112019025034A2/pt unknown
- 2018-05-30 DK DK18728153.0T patent/DK3630177T5/da active
- 2018-05-30 IL IL270855A patent/IL270855B2/en unknown
- 2018-05-30 CN CN201880035726.5A patent/CN110678201A/zh active Pending
- 2018-05-30 EP EP23190328.7A patent/EP4268900A3/fr active Pending
- 2018-05-30 WO PCT/EP2018/064229 patent/WO2018220040A1/fr not_active Ceased
- 2018-05-30 RS RS20230937A patent/RS64746B1/sr unknown
2019
- 2019-11-06 ZA ZA2019/07369A patent/ZA201907369B/en unknown
- 2019-11-28 MX MX2023013228A patent/MX2023013228A/es unknown
2023
- 2023-10-20 CY CY20231100585T patent/CY1126559T1/el unknown
- 2023-12-06 JP JP2023205931A patent/JP2024028865A/ja active Pending
2024
- 2024-07-18 US US18/776,362 patent/US20250186460A1/en active Pending
2025
- 2025-05-13 AU AU2025203436A patent/AU2025203436A1/en active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013024095A1 (fr) *	2011-08-16	2013-02-21	Morphosys Ag	Polythérapie avec anticorps anti-cd19 et analogue de purine
WO2013024097A1 (fr) *	2011-08-16	2013-02-21	Morphosys Ag	Polythérapie avec anticorps anti-cd19 et moutarde à l'azote
WO2018078123A1 (fr) *	2016-10-28	2018-05-03	Morphosys Ag	Combinaison d'anticorps anti-cd19 avec un inhibiteur de bcl -2 et utilisations de celle-ci

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOXHAMMER: "ACTIVITY OF THE CD19 ANTIBODY MOR208 IN COMBINATION WITH IBRUTINIB, IDELALISIB OR VENETOCLAX IN VITRO", EHA LEARNING CENTER, 18 May 2017 (2017-05-18), pages 1 - 2, XP055404016, Retrieved from the Internet <URL:https://learningcenter.ehaweb.org/eha/2017/22nd/182482/rainer.boxhammer.activity.of.the.cd19.antibody.mor208.in.combination.with.html> [retrieved on 20170905] *
CLINICALTRIALS.GOV: "NCT02639910 : A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor", 21 May 2017 (2017-05-21), pages 1 - 4, XP055404017, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT02639910/2017_05_21> [retrieved on 20170905] *
S C H KARLSSON ET AL: "Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy", CANCER GENE THERAPY, vol. 20, no. 7, 21 June 2013 (2013-06-21), GB, pages 386 - 393, XP055403655, ISSN: 0929-1903, DOI: 10.1038/cgt.2013.35 *

Also Published As

Publication number	Publication date
RU2019139552A (ru)	2021-07-01
IL297461B1 (en)	2024-05-01
SG11201909715VA (en)	2019-11-28
IL270855B (en)	2022-11-01
MX2023013228A (es)	2024-04-16
US20250186460A1 (en)	2025-06-12
AU2018276384A1 (en)	2019-11-07
RU2019139552A3 (fr)	2021-09-22
SI3630177T1 (sl)	2023-12-29
FI3630177T3 (fi)	2023-10-18
MD3630177T2 (ro)	2024-01-31
AU2018276384B2 (en)	2025-02-13
MA48751A (fr)	2020-04-08
IL270855B2 (en)	2023-03-01
WO2018220040A1 (fr)	2018-12-06
MX2019014330A (es)	2020-02-05
KR20240117655A (ko)	2024-08-01
BR112019025034A2 (pt)	2020-06-30
HRP20231229T1 (hr)	2024-02-02
PL3630177T3 (pl)	2024-04-08
CN110678201A (zh)	2020-01-10
AU2025203436A1 (en)	2025-06-05
MA48751B1 (fr)	2023-11-30
HUE063119T2 (hu)	2024-01-28
EP3630177B1 (fr)	2023-08-09
DK3630177T5 (da)	2024-09-02
DK3630177T3 (da)	2023-10-16
LT3630177T (lt)	2023-10-25
JP2020521777A (ja)	2020-07-27
SMT202300338T1 (it)	2023-11-13
ES2961940T3 (es)	2024-03-14
RS64746B1 (sr)	2023-11-30
EP3630177A1 (fr)	2020-04-08
CA3062400A1 (fr)	2018-12-06
KR20200010472A (ko)	2020-01-30
JP7399713B2 (ja)	2023-12-18
PT3630177T (pt)	2023-11-10
IL297461B2 (en)	2024-09-01
EP4268900A2 (fr)	2023-11-01
IL297461A (en)	2022-12-01
JP2024028865A (ja)	2024-03-05
CY1126559T1 (el)	2026-02-25
IL270855A (en)	2020-01-30
ZA201907369B (en)	2024-04-24

Legal Events

Date	Code	Title	Description
2023-09-29	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2023-09-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED
2023-11-01	AC	Divisional application: reference to earlier application	Ref document number: 3630177 Country of ref document: EP Kind code of ref document: P
2023-11-01	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-01-30	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61P0035000000 Ipc: A61K0039395000
2024-02-02	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2024-03-06	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-03-06	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 35/00 20060101ALI20240130BHEP Ipc: C07K 16/28 20060101ALI20240130BHEP Ipc: A61K 31/00 20060101ALI20240130BHEP Ipc: A61K 39/395 20060101AFI20240130BHEP
2024-06-26	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20240522
2024-07-26	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40104369 Country of ref document: HK
2024-09-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2024-10-16	17P	Request for examination filed	Effective date: 20240906
2024-10-16	RAV	Requested validation state of the european patent: fee paid	Extension state: TN Effective date: 20240906 Extension state: MD Effective date: 20240906 Extension state: MA Effective date: 20240906 Extension state: KH Effective date: 20240906
2024-10-16	RAX	Requested extension states of the european patent have changed	Extension state: ME Payment date: 20240906 Extension state: BA Payment date: 20240906
2024-10-16	RBV	Designated contracting states (corrected)	Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2025-05-14	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: INCYTE CORPORATION
2026-01-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2026-03-04	17Q	First examination report despatched	Effective date: 20260128

Publication	Publication Date	Title
ZA201907369B (en)	2024-04-24	Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
PH12021550553A1 (en)	2022-02-28	Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell
MX2021006681A (es)	2021-11-17	Anticuerpos anti-claudina y usos de los mismos.
MX2024015039A (es)	2025-01-09	Composiciones anti-cd24 y usos de las mismas
WO2018187227A8 (fr)	2018-11-15	Procédés de traitement du cancer à l'aide d'anticorps ciblant ps avec des agents immuno-oncologiques
EP4400173A3 (fr)	2025-02-12	Anticorps anti-sirp alpha
EP4344706A3 (fr)	2024-05-22	Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste de l'il-4r
WO2017214207A3 (fr)	2018-01-18	Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
WO2015181641A3 (fr)	2016-01-21	Combinaison de lénalidomide et d'une construction de polypeptide, et ses utilisations
NZ737418A (en)	2025-05-02	Anti-ntb-a antibodies and related compositions and methods
MX353589B (es)	2018-01-19	Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.
PH12019500643A1 (en)	2019-07-29	Antibodies that bind interleukin-2 and uses thereof
EP4406550A3 (fr)	2024-10-16	Anticorps anti-cd40 à activité agoniste améliorée
SA520420109B1 (ar)	2023-12-21	أجسام مضادة
MX2021005761A (es)	2021-08-11	Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados.
MX2023004314A (es)	2023-05-04	Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
MX354479B (es)	2018-03-07	Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.
MX2022016270A (es)	2023-02-15	Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.
MX2016011295A (es)	2017-05-08	Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2.
WO2016191675A3 (fr)	2017-02-16	Anticorps contre le glypicane-3 et leurs utilisations dans le diagnostic et le traitement du cancer
MX2022006154A (es)	2022-10-07	Combinaciones y sus usos.
MX2009010269A (es)	2009-10-12	Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
EP4488288A3 (fr)	2025-04-16	Moyens et procédés pour la thérapie génique aav chez l'homme
MY209449A (en)	2025-07-09	Anti-cd19 therapy in patients having a limited number of nk cells
MY206426A (en)	2024-12-17	Anti-cd38 antibodies and formulations